FDA Confirms AFPs Not Permissible Under Section 804
On August, 28, 2024, Aimed Alliance received an interim response from the Food and Drug Administration regarding its Citizen Petition on…
Browsing: Policymakers
Minnesota Reports $1.34 Billion in 340B Revenue
Minnesota’s second year of 340B reporting shows that Covered Entities generated at least $1.34 billion in net 340B revenue in…
Aimed Alliance Urges Maryland PDAB to Protect Patient Access in UPL Deliberations
Aimed Alliance sent letters to the Maryland PDAB urging it to proceed cautiously with setting a UPL for Jardiance and…
GLOBE Model Expected to Have Minimal Impact on Part B OOP Costs
A new analysis published by Avalere Health found that the proposed GLOBE (Global Benchmark for Efficient Drug Pricing) Model would have…
New Report – International Reference Pricing: Lessons Learned from Abroad
For decades, rising costs of health care, health insurance, and prescription drugs have been a major concern for American consumers, caregivers,…
Aimed Alliance Urges Reconsideration of VA PDAB Bill
Aimed Alliance recently sent a letter urging the Virginia House Labor and Commerce Committee to reconsider House Bill 483, which…
Aimed Alliance Releases New Explainer on 340B Program
On October 22, Aimed Alliance published a new resource on the 340B Drug Pricing Program (340B Program). The 340B program…
Aimed Alliance & NORM Release 2026 Open Enrollment Brochures
The 2026 Open Enrollment period is fast approaching! The 2026 Open Enrollment period for Medicare Advantage plans is October 15,…
Aimed Alliance Urges Stronger Consumer Protections in CO Bill on AFPs
Aimed Alliance sent a letter to Colorado Representative Ken DeGraaf regarding his special session bill, “Prescription Drug Benefit Information Transparency” (HB25B-1012).…
Colorado Sets Nation’s First UPL, Raising Patient Safeguards Concerns
On October 3, the Colorado Prescription Drug Affordability Board (PDAB) voted to establish an upper payment limit (UPL) for Enbrel,…